Patents by Inventor Ryutaro Nakashima

Ryutaro Nakashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11131940
    Abstract: A toner for developing an electrostatic charge image includes a binder resin. In dynamic viscoelasticity measurement, a storage modulus G?50T of the toner at 50° C. is 2×106 Pa or more and 3×108 Pa or less, a storage modulus G?100T of the toner at 100° C. is 1×104 Pa or more and 1×106 Pa or less, and tan ?T of the toner in an entire temperature range of 50° C. or more and 100° C. or less is 0.05 or more and 1.5 or less.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: September 28, 2021
    Assignee: FUJIFILM Business Innovation Corp.
    Inventors: Shinya Sakamoto, Shinya Nakashima, Masaki Iwase, Tomohiro Shinya, Ryutaro Kembo, Tomohito Nakajima, Naomi Miyamoto
  • Patent number: 8754112
    Abstract: Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: June 17, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shigeo Yamanoi, Hidenori Namiki, Takahiro Katagiri, Mayuko Akiu, Katsuji Kagechika, Takeshi Honda, Koji Matsumoto, Ryutaro Nakashima
  • Patent number: 8557802
    Abstract: Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: October 15, 2013
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shigeo Yamanoi, Hidenori Namiki, Takahiro Katagiri, Mayuko Akiu, Katsuji Kagechika, Takeshi Honda, Koji Matsumoto, Ryutaro Nakashima
  • Patent number: 8222281
    Abstract: To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ?C(R5)- or ?N—; Y represents —O— or —NH—; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; R1 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 aliphatic acyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C6-C10 aryl group; and R2, R3, R4, and R5 may be the same or different and each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 alkoxy group, or a nitro group.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: July 17, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Narihiro Toda, Masao Yoshida, Rieko Takano, Masahiro Inoue, Takeshi Honda, Koji Matsumoto, Ryutaro Nakashima
  • Publication number: 20120129891
    Abstract: Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 24, 2012
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shigeo Yamanoi, Hidenori Namiki, Takahiro Katagiri, Mayuko Akiu, Katsuji Kagechika, Takeshi Honda, Koji Matsumoto, Ryutaro Nakashima
  • Publication number: 20120129832
    Abstract: Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 24, 2012
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shigeo Yamanoi, Hidenori Namiki, Takahiro Katagiri, Mayuko Akiu, Katsuji Kagechika, Takeshi Honda, Koji Matsumoto, Ryutaro Nakashima
  • Publication number: 20110053974
    Abstract: To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ?C(R5)- or ?N—; Y represents —O— or —NH—; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; R1 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 aliphatic acyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C6-C10 aryl group; and R2, R3, R4, and R5 may be the same or different and each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 alkoxy group, or a nitro group.
    Type: Application
    Filed: September 29, 2010
    Publication date: March 3, 2011
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Masao YOSHIDA, Rieko TAKANO, Masahiro INOUE, Takeshi HONDA, Koji MATSUMOTO, Ryutaro NAKASHIMA
  • Publication number: 20090227493
    Abstract: The present invention provides a pharmaceutical composition (preferably a drug for therapeutic and/or prophylactic treatment of diabetes) comprising a GLP-1 receptor agonist and the insulin resistance improving agent 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, or a pharmacologically acceptable salt thereof, in combination.
    Type: Application
    Filed: May 26, 2006
    Publication date: September 10, 2009
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ryutaro Nakashima, Junko Ogawa, Akira Okuno
  • Publication number: 20090124626
    Abstract: To provide a method for treating diabetes which has an excellent hypoglycemic action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor and an insulin sensitizer in combination.
    Type: Application
    Filed: March 27, 2008
    Publication date: May 14, 2009
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shoichi Kanda, Ryutaro Nakashima